\n
Bipolar dysfunction disrupts\u00a0every day life, inflicting extreme shifts in temper and power, flipping between excessive highs and deep lows. Most\u00a0sufferers\u00a0who’re prescribed at present out there medication\u00a0for the situation\u00a0like temper stabilizers\u00a0don\u2019t\u00a0profit a lot from them,\u00a0and as an alternative,\u00a0should\u00a0grapple with unintended effects from these medicines. The\u00a0demand for\u00a0new\u00a0therapies\u00a0which can be\u00a0each efficient and\u00a0not related to important unintended effects\u00a0is\u00a0urgent.\u00a0New therapies within the clinic hope to satisfy this demand.\u00a0<\/p>\n
Present requirements of care:\u00a0affected person\u00a0wants\u00a0unmet\u00a0\u00a0<\/h2>\n
Bipolar dysfunction impacts\u00a0greater than 40 million individuals on the earth, and the depressive part is the predominant and most disabling state for\u00a0the vast majority of\u00a0sufferers.\u00a0It causes bodily modifications within the mind\u2019s emotion management\u00a0facilities\u00a0and the chemical messengers, which then disrupt\u00a0how the emotional and considering\u00a0facilities\u00a0talk. \u00a0\u00a0<\/p>\n
The situation\u00a0is marked by persistent low temper, lack of curiosity, fatigue, and impaired functioning. Sufferers lose a median of a couple of month of labor every year and face elevated dangers of hospitalization and suicide.\u00a0\u00a0<\/p>\n
The present normal of care depends\u00a0largely on\u00a0temper stabilizers and atypical antipsychotics, usually utilized in mixture,\u00a0defined Kevin Finney,\u00a0president and\u00a0chief govt officer (CEO)\u00a0of Autobahn Therapeutics, a California-based\u00a0neurodrug\u00a0developer.\u00a0\u00a0<\/p>\n
\u201cGreater than half of\u00a0the\u00a0sufferers don’t obtain enough aid from at present out there therapies, that are restricted by modest efficacy and important unintended effects, together with weight achieve, sexual dysfunction, motion problems, and metabolic problems. For a lot of sufferers, these unintended effects compound the very signs they’re already managing,\u201d mentioned Finney.\u00a0<\/p>\n
He identified that this burden is\u00a0evident\u00a0in atypical despair, \u201ca outstanding and extremely underserved subpopulation.\u201d It’s characterised by\u00a0heightened\u00a0urge for food, hypersomnia, and low power.\u00a0<\/p>\n
\u201cSome standard-of-care remedies actively worsen these signs, and there was no essentially new mechanism of motion accredited in bipolar despair in years,\u201d mentioned Finney, whose firm is\u00a0creating a therapy for\u00a0the situation.\u00a0<\/p>\n
Autobahn Therapeutics\u2019\u00a0elunetirom\u00a0reaps optimistic medical outcomes\u00a0<\/h2>\n
Autobahn\u2019s\u00a0elunetirom\u00a0is an oral, once-daily, brain-targeted thyroid hormone receptor agonist, which acts as a central nervous system (CNS)-selective thyroid hormone receptor beta agonist.\u00a0\u00a0<\/p>\n
\u201cIt’s designed to do one thing completely different from basically each antidepressant developed over the past 40 years,\u201d mentioned Finney.\u00a0<\/p>\n
Fairly than modulating neurotransmitters like serotonin, dopamine, or norepinephrine, Finney defined that\u00a0elunetirom\u00a0targets thyroid hormone receptors within the mind to spice up mobile power and drive neuroplasticity, the mind\u2019s capacity to kind and strengthen connections. In different phrases, it’s designed to assist restore wholesome mind operate quite than merely handle signs. As\u00a0at present accredited remedies are inclined to not be\u00a0efficacious sufficient\u00a0or have\u00a0poor tolerability\u00a0in\u00a0sufferers, these unmet wants are what\u00a0elunetirom\u00a0is designed to handle.\u00a0<\/p>\n
It’s\u00a0much like\u00a0the neuroplasticity mechanism\u00a0that psychedelics\u00a0comply with, Finney defined. \u201cIt’s the similar pathway behind a lot of the joy round psychedelics.\u201d\u00a0<\/p>\n
The distinction, nevertheless, is that the drug comes\u00a0with no psychoactive results and,\u00a0it being a once-daily oral pill, there isn’t a therapy burden as\u00a0sufferers can take it at dwelling with out having to\u00a0make frequent\u00a0visits to\u00a0the clinic.\u00a0<\/p>\n
Artificial thyroid hormones\u00a0have\u00a0been used\u00a0off-label\u00a0in despair for greater than 50 years, which provide many years of human proof that this pathway issues in temper.\u00a0\u00a0<\/p>\n
\u201cThe underlying biology is just not new,\u201d mentioned Finney. \u201cWhat has been lacking is a solution to entry that profit within the mind with out the peripheral results of thyroid hormone, corresponding to results on the center. That’s the downside\u00a0elunetirom\u00a0is constructed to resolve: bringing the advantage of thyroid hormone biology to the mind whereas limiting exercise in the remainder of the physique.\u201d\u00a0<\/p>\n
Topline outcomes\u00a0from a part 2 research in 21 sufferers\u00a0shed some gentle on the drug\u2019s profit.\u00a0Sufferers got\u00a0elunetirom\u00a0together with their common therapy regiment, which\u00a0includes\u00a0temper stabilizers and antipsychotics. The candidate\u00a0was discovered to efficiently scale back despair severity in sufferers with bipolar dysfunction. About 75% of sufferers responded to the therapy after six weeks and 50% of them have been in remission by then. A statistically important 16.8-point\u00a0Hamilton Melancholy Ranking Scale (HAMD)-17 enchancment was noticed, hitting the first endpoint of the research.\u00a0The\u00a0HAMD-17 is a check used to measure the severity of despair in sufferers and to verify how nicely\u00a0a\u00a0therapy is working.\u00a0\u00a0<\/p>\n
\u201cFor the tens of millions of individuals residing with bipolar despair who haven’t discovered enough aid, these just lately reported knowledge provide actual encouragement,\u201d mentioned Finney. \u201cSimply as essential, we noticed the onset of statistically important enchancment as early as week two, which factors to a fast antidepressant impact. And\u00a0elunetirom\u00a0was protected and well-tolerated, with no extreme or critical treatment-related adversarial occasions.\u201d\u00a0<\/p>\n
Sufferers improved throughout the signs linked to atypical despair, together with power, sleep, and urge for food, that are the areas that right this moment\u2019s remedies usually make worse, Finney identified.\u00a0<\/p>\n
\u201cThe patient-reported measures advised the identical story,\u201d he\u00a0mentioned. \u201cThe practical restoration was simply as hanging.\u201d\u00a0<\/p>\n
Sufferers reported feeling \u201cconsiderably higher\u201d primarily based on the Affected person World Impression and the Signs of Melancholy Questionnaire.\u00a0High quality of life improved too.\u00a0Sufferers\u00a0who entered the research\u00a0have been dropping\u00a0a median of two.7 days of labor every week. This dropped to 0.4 days after six weeks of taking\u00a0elunetirom.\u00a0<\/p>\n
\u201cFor individuals who have lived with this sickness for years, restoring that a lot every day functioning is profound,\u201d mentioned Finney.\u00a0<\/p>\n
In the meantime,\u00a0Israeli firm\u00a0Syremis\u00a0Therapeutics\u00a0launched\u00a0with $165 million late final 12 months to sort out\u00a0despair\u00a0related to\u00a0bipolar dysfunction, main depressive dysfunction, and schizophrenia.\u00a0Its candidate\u00a0for bipolar despair, nevertheless,\u00a0is an NMDA receptor antagonist.\u00a0ST-901, which is within the investigational new drug (IND)-enabling stage, is supposed to work by blocking\u00a0the NMDA (N-methyl-D-aspartate) receptor. This receptor\u00a0controls\u00a0glutamate ranges \u2013 the mind\u2019s principal\u00a0excitatory neurotransmitter.\u00a0By regulating glutamate, ST-901 might stop its overactivation, thereby resetting mind chemistry in despair.\u00a0<\/p>\n
Focusing on glutamate: RAP-219 for mania\u00a0<\/h2>\n
Mania is a core symptom of bipolar dysfunction.\u00a0It impacts the mind by hyper-activating the\u00a0amygdala, the\u00a0emotional\u00a0middle\u00a0of the mind,\u00a0and dulls the prefrontal cortex, which\u00a0is liable for\u00a0judgement and impulse management. As dopamine tends to spike throughout manic episodes, the\u00a0amygdala\u00a0goes into overdrive.\u00a0\u00a0<\/p>\n
Rapport Therapeutics\u2019 RAP-219\u00a0is designed to focus on the TARP\u03b38 protein, a helper protein connected solely to AMPA receptors\u00a0in particular components of the mind. These AMPA receptors reply to glutamate. As soon as RAP-219 binds to a particular a part of the receptor, it modifications the form\u00a0in order to\u00a0dial down overactive mind alerts.\u00a0\u00a0<\/p>\n
Topline outcomes of a part 2 trial are anticipated later this 12 months, after which the corporate hopes to have interaction in talks with the U.S. Meals and Drug Administration\u00a0(FDA)\u00a0to doubtlessly design a part 3 program and plan for a brand new drug software to deal with bipolar mania.\u00a0<\/p>\n
Additionally in part 2 trials is\u00a0ALTO-100. Developed by Alto Neuroscience in California,\u00a0ALTO-100\u00a0is one other\u00a0oral small molecule\u00a0that’s designed\u00a0to\u00a0improve\u00a0neural plasticity within the hippocampus, a mind area essential for each cognition and temper.\u00a0In response to the corporate, it builds on\u00a0the understanding\u00a0that despair is partly pushed by a discount in hippocampal\u00a0neuroplasticity and\u00a0is\u00a0focused to these sufferers who\u00a0lack\u00a0this\u00a0neuroplasticity,\u00a0which is\u00a0the mind\u2019s capacity to rewire and construct new connections.\u00a0\u00a0<\/p>\n
ALTO-100 is at present in\u00a0part 2b improvement for the therapy of bipolar despair\u00a0on prime of the usual of care.\u00a0Topline outcomes are anticipated\u00a0this 12 months.\u00a0<\/p>\n
With\u00a0trials\u00a0ongoing, it appears to be like like 2026 can be a 12 months\u00a0of\u00a0pivotal readouts\u00a0for potential bipolar dysfunction remedies.\u00a0Elunetirom\u00a0leads\u00a0the cost\u00a0with its encouraging part 2 outcomes, in addition to\u00a0its latest Quick Monitor Designation from the FDA.\u00a0<\/p>\n
Finney foresees a path\u00a0for\u00a0elunetirom\u2019s\u00a0approval. He mentioned: \u201cWith a powerful bipolar dataset in hand and main depressive dysfunction knowledge coming later this 12 months, we consider\u00a0elunetirom\u00a0has the potential to develop into a franchise-defining therapy throughout a number of types of despair.\u201d\u00a0<\/p>\n<\/div>\n
\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Bipolar dysfunction disrupts\u00a0every day life, inflicting extreme shifts in temper and power, flipping between excessive highs and deep lows. Most\u00a0sufferers\u00a0who’re prescribed at present out there medication\u00a0for the situation\u00a0like temper stabilizers\u00a0don\u2019t\u00a0profit a lot from them,\u00a0and as an alternative,\u00a0should\u00a0grapple with unintended effects from these medicines. The\u00a0demand for\u00a0new\u00a0therapies\u00a0which can be\u00a0each efficient and\u00a0not related to important unintended effects\u00a0is\u00a0urgent.\u00a0New therapies […]<\/p>\n","protected":false},"author":1,"featured_media":2383,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/bipolar-disorder-treatments.jpg","fifu_image_alt":"","jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_override_bookmark_settings":[],"jnews_social_meta":[],"jnews_override_counter":[],"footnotes":""},"categories":[10],"tags":[2740,2870,2871,2872,1020,1548,1380],"class_list":["post-2381","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","tag-accelerate","tag-approval","tag-biotechs","tag-bipolar","tag-disorder","tag-race","tag-therapies"],"yoast_head":"\n
Race for approval: biotechs speed up bipolar dysfunction therapies - Future News 24<\/title>\n<meta name=\"description\" content=\"New therapies in the clinic for bipolar disorder hope to meet unmet needs of efficacy and minimal side effects.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/futurenews24.com\/index.php\/2026\/07\/15\/bipolar-disorder-therapies-biotechs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Race for approval: biotechs speed up bipolar dysfunction therapies - Future News 24\" \/>\n<meta property=\"og:description\" content=\"New therapies in the clinic for bipolar disorder hope to meet unmet needs of efficacy and minimal side effects.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/futurenews24.com\/index.php\/2026\/07\/15\/bipolar-disorder-therapies-biotechs\/\" \/>\n<meta property=\"og:site_name\" content=\"Future News 24\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-15T13:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-15T18:59:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/bipolar-disorder-treatments.jpg\" \/>\n<meta name=\"author\" content=\"Future News 24\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/bipolar-disorder-treatments.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Future News 24\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/15\\\/bipolar-disorder-therapies-biotechs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/15\\\/bipolar-disorder-therapies-biotechs\\\/\"},\"author\":{\"name\":\"Future News 24\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/person\\\/cecad1bde21cfc357cf70128144d6c83\"},\"headline\":\"Race for approval: biotechs speed up bipolar dysfunction therapies\",\"datePublished\":\"2026-07-15T13:00:00+00:00\",\"dateModified\":\"2026-07-15T18:59:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/15\\\/bipolar-disorder-therapies-biotechs\\\/\"},\"wordCount\":1366,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/15\\\/bipolar-disorder-therapies-biotechs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/bipolar-disorder-treatments.jpg\",\"keywords\":[\"Accelerate\",\"approval\",\"biotechs\",\"bipolar\",\"disorder\",\"race\",\"therapies\"],\"articleSection\":[\"BioTechnology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/15\\\/bipolar-disorder-therapies-biotechs\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/15\\\/bipolar-disorder-therapies-biotechs\\\/\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/15\\\/bipolar-disorder-therapies-biotechs\\\/\",\"name\":\"Race for approval: biotechs speed up bipolar dysfunction therapies - Future News 24\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/15\\\/bipolar-disorder-therapies-biotechs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/15\\\/bipolar-disorder-therapies-biotechs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/bipolar-disorder-treatments.jpg\",\"datePublished\":\"2026-07-15T13:00:00+00:00\",\"dateModified\":\"2026-07-15T18:59:13+00:00\",\"description\":\"New therapies in the clinic for bipolar disorder hope to meet unmet needs of efficacy and minimal side effects.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/15\\\/bipolar-disorder-therapies-biotechs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/15\\\/bipolar-disorder-therapies-biotechs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/15\\\/bipolar-disorder-therapies-biotechs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/bipolar-disorder-treatments.jpg\",\"contentUrl\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/bipolar-disorder-treatments.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/15\\\/bipolar-disorder-therapies-biotechs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/futurenews24.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Race for approval: biotechs speed up bipolar dysfunction therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#website\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/\",\"name\":\"Future News 24\",\"description\":\"The Smart Hub for AI and Next-Gen Innovation\",\"publisher\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/futurenews24.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\",\"name\":\"Future News 24\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/fn24-favicon.png\",\"contentUrl\":\"https:\\\/\\\/futurenews24.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/fn24-favicon.png\",\"width\":250,\"height\":250,\"caption\":\"Future News 24\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/person\\\/cecad1bde21cfc357cf70128144d6c83\",\"name\":\"Future News 24\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"caption\":\"Future News 24\"},\"sameAs\":[\"https:\\\/\\\/futurenews24.com\"],\"url\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/author\\\/mridulpahuja20\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Race for approval: biotechs speed up bipolar dysfunction therapies - Future News 24","description":"New therapies in the clinic for bipolar disorder hope to meet unmet needs of efficacy and minimal side effects.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/futurenews24.com\/index.php\/2026\/07\/15\/bipolar-disorder-therapies-biotechs\/","og_locale":"en_US","og_type":"article","og_title":"Race for approval: biotechs speed up bipolar dysfunction therapies - Future News 24","og_description":"New therapies in the clinic for bipolar disorder hope to meet unmet needs of efficacy and minimal side effects.","og_url":"https:\/\/futurenews24.com\/index.php\/2026\/07\/15\/bipolar-disorder-therapies-biotechs\/","og_site_name":"Future News 24","article_published_time":"2026-07-15T13:00:00+00:00","article_modified_time":"2026-07-15T18:59:13+00:00","og_image":[{"url":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/bipolar-disorder-treatments.jpg","type":"","width":"","height":""}],"author":"Future News 24","twitter_card":"summary_large_image","twitter_image":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/bipolar-disorder-treatments.jpg","twitter_misc":{"Written by":"Future News 24","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/15\/bipolar-disorder-therapies-biotechs\/#article","isPartOf":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/15\/bipolar-disorder-therapies-biotechs\/"},"author":{"name":"Future News 24","@id":"https:\/\/futurenews24.com\/#\/schema\/person\/cecad1bde21cfc357cf70128144d6c83"},"headline":"Race for approval: biotechs speed up bipolar dysfunction therapies","datePublished":"2026-07-15T13:00:00+00:00","dateModified":"2026-07-15T18:59:13+00:00","mainEntityOfPage":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/15\/bipolar-disorder-therapies-biotechs\/"},"wordCount":1366,"commentCount":0,"publisher":{"@id":"https:\/\/futurenews24.com\/#organization"},"image":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/15\/bipolar-disorder-therapies-biotechs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/bipolar-disorder-treatments.jpg","keywords":["Accelerate","approval","biotechs","bipolar","disorder","race","therapies"],"articleSection":["BioTechnology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/futurenews24.com\/index.php\/2026\/07\/15\/bipolar-disorder-therapies-biotechs\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/15\/bipolar-disorder-therapies-biotechs\/","url":"https:\/\/futurenews24.com\/index.php\/2026\/07\/15\/bipolar-disorder-therapies-biotechs\/","name":"Race for approval: biotechs speed up bipolar dysfunction therapies - Future News 24","isPartOf":{"@id":"https:\/\/futurenews24.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/15\/bipolar-disorder-therapies-biotechs\/#primaryimage"},"image":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/15\/bipolar-disorder-therapies-biotechs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/bipolar-disorder-treatments.jpg","datePublished":"2026-07-15T13:00:00+00:00","dateModified":"2026-07-15T18:59:13+00:00","description":"New therapies in the clinic for bipolar disorder hope to meet unmet needs of efficacy and minimal side effects.","breadcrumb":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/15\/bipolar-disorder-therapies-biotechs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/futurenews24.com\/index.php\/2026\/07\/15\/bipolar-disorder-therapies-biotechs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/15\/bipolar-disorder-therapies-biotechs\/#primaryimage","url":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/bipolar-disorder-treatments.jpg","contentUrl":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/bipolar-disorder-treatments.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/15\/bipolar-disorder-therapies-biotechs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/futurenews24.com\/"},{"@type":"ListItem","position":2,"name":"Race for approval: biotechs speed up bipolar dysfunction therapies"}]},{"@type":"WebSite","@id":"https:\/\/futurenews24.com\/#website","url":"https:\/\/futurenews24.com\/","name":"Future News 24","description":"The Smart Hub for AI and Next-Gen Innovation","publisher":{"@id":"https:\/\/futurenews24.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/futurenews24.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/futurenews24.com\/#organization","name":"Future News 24","url":"https:\/\/futurenews24.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/futurenews24.com\/#\/schema\/logo\/image\/","url":"https:\/\/futurenews24.com\/wp-content\/uploads\/2026\/06\/fn24-favicon.png","contentUrl":"https:\/\/futurenews24.com\/wp-content\/uploads\/2026\/06\/fn24-favicon.png","width":250,"height":250,"caption":"Future News 24"},"image":{"@id":"https:\/\/futurenews24.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/futurenews24.com\/#\/schema\/person\/cecad1bde21cfc357cf70128144d6c83","name":"Future News 24","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","caption":"Future News 24"},"sameAs":["https:\/\/futurenews24.com"],"url":"https:\/\/futurenews24.com\/index.php\/author\/mridulpahuja20\/"}]}},"_links":{"self":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/2381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/comments?post=2381"}],"version-history":[{"count":1,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/2381\/revisions"}],"predecessor-version":[{"id":2382,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/2381\/revisions\/2382"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/media\/2383"}],"wp:attachment":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/media?parent=2381"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/categories?post=2381"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/tags?post=2381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}